NCT05389722

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

A Phase 1, Parallel-group, 3-part, 2-period, Fixed-sequence, Crossover, Open-label, Nonrandomized, Drug-drug Interaction Study to Assess the Pharmacokinetics of CC-92480 (BMS-986348) After Coadministration With Rifampin and Itraconazole, and Pharmacokinetics of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	CC-92480	Specified dose on specified days
DRUG	Rifampin	Specified dose on specified days
DRUG	Itraconazole	Specified dose on specified days
DRUG	Digoxin	Specified dose on specified days
DRUG	Rosuvastatin	Specified dose on specified days

Timeline

• Start date: 2022-06-09
• Primary completion: 2022-11-12
• Completion: 2022-11-12
• First posted: 2022-05-25
• Last updated: 2023-04-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study